In a recent overview about the role of biomarkers for the prediction of response to checkpoint immunotherapy 65, it is shown that cervical cancer is frequently positive for PD-L1, and show a moderate mutational burden, with 5-6 mutations per megabase. The gene discussed is CD274; the disease is cervical carcinoma.